Navigation Links
Seventh Sense Biosystems Receives CE Mark Approval for its Touch Activated Phlebotomy Blood Collection and Testing System
Date:11/4/2013

CAMBRIDGE, Mass., Nov. 4, 2013 /PRNewswire/ -- Seventh Sense Biosystems, Inc., the leading developer of painless blood collection and diagnostic platforms, today announced it has obtained CE Mark approval for its Touch Activated Phlebotomy (TAP™) platform for blood collection and testing.

"This first regulatory approval is a significant milestone in our goal of expanding the reach of blood-based point-of-care diagnostics to a majority of patients, regardless of geography or setting," said Howard Weisman, CEO and President of Seventh Sense. "When fully commercialized, the TAP platform will incorporate additional capabilities for sample separation as well as dried blood spot and on-board diagnostic capabilities."

Studies show that a positive patient experience is closely linked to compliance with a prescribed treatment. Seventh Sense will be developing and commercializing novel diagnostic tools that are specially engineered to eliminate the pain and anxiety that can prevent patients from receiving appropriate care. The company's proprietary innovations in microneedle and microfluidic technology enable the collection of a stable, secure and high quality blood sample without painful lancing or the need for highly skilled medical personnel.

"We've surveyed patients and their physicians around the world and found a significant need for near painless, simple-to-use, and reliable blood collection and diagnostic devices that has so far been unmet," said Weisman.

The company plans to scale-up manufacturing capability in 2014 and continue the development of follow-on products for patients and clinicians in the Americas, Europe and Asia-Pacific regions.

About the Touch Activated Phlebotomy Device
Touch Activated Phlebotomy (TAP™) is a proprietary platform that draws capillary blood in a painless, one-step process without having to access a vein and it can be utilized across and integrated with a broad spectrum of diagnostic applications. The TAP system penetrates the uppermost layers of skin through the use of micro-needles, collects capillary blood using a novel microfluidic extraction process, and stabilizes the blood with anticoagulant if required. The device has a visual indicator to confirm that collection is complete. The TAP platform is designed for fully automated, high throughput manufacturing.

About Seventh Sense Biosystems, Inc.
Founded in 2008, within Flagship VentureLabs™, Seventh Sense is developing an array of products based on the company's proprietary Touch Activated Phlebotomy (TAP™) painless blood collection platform, with an initial focus on enabling important diagnostic testing at the point of care by reducing the discomfort, anxiety and hassle of blood sample collection.  Seventh Sense is backed by leading investors Flagship Ventures and Polaris Partners.  For more information, please visit www.7sbio.com.

For media inquiries contact:
Tim Richards
617-547-7246  ext. 222
info@7sbio.com

 


'/>"/>
SOURCE Seventh Sense Biosystems, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Hyland Software Hosts Seventh Annual OnBase/Epic User Forum
2. AUL Files Seventh Brief Supporting First Amendment Freedom of Conscience
3. Volcano Corporation Announces Webcast Of March Seventh Analyst Day
4. 3-V Biosciences To Present at the Seventh Annual JMP Securities Healthcare Conference
5. Arena Pharmaceuticals to Present at the Seventh Annual JMP Securities Healthcare Conference
6. Israeli Medical Device Company FlowSense Acquired by Baxter
7. iSonea Receives Frost & Sullivan New Product Innovation Leadership Award for its Path-Breaking Mobile Asthma Monitoring App, AsthmaSense
8. AuraSense Therapeutics Closes Tranche II of Series B Equity Investment
9. Deceptive Practices By Illegal Online Drug Sellers Give Consumers a False Sense of Legitimacy and Safety, Reports NABP
10. Xenon Licenses Antisense Drug XEN701 From Isis and Initiates Preclinical Toxicology Studies
11. Clinical Team Researching the Impact of the EarlySense System Wins Best Novel Idea Prize at the Rapid Response Systems and Medical Emergency Teams 2013 8th International Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... 19, 2017 Global Prostate Cancer Therapeutics ... the prostate cancer therapeutics market analyzes the current ... prevalence of prostate cancer, launch of promising emerging ... of new drugs & therapeutic biological products, and ... to lesser side effects are some of the ...
(Date:4/19/2017)... , April 19, 2017  Sorrento Therapeutics, Inc. ... clinical-stage biopharmaceutical company developing new treatments for cancer ... closing of its previously announced underwritten public offering ... a public offering price of $2.00 per share, ... offering expenses payable by Sorrento.  The net proceeds ...
(Date:4/19/2017)... , April 19, 2017  Novartis today announced ... National Heart, Lung, and Blood Institute (NHLBI) of ... 58% of patients with treatment-naïve severe aplastic anemia ... treated with eltrombopag at the initiation of and ... study evaluated three sequential treatment groups, or cohorts. ...
Breaking Medicine Technology:
(Date:4/24/2017)... ... ... As part of the nationwide Days of Remembrance effort led by the United ... persecution, Center for Medicine after the Holocaust (CMATH) announced that it will ... and Poland next week. , The Fourth Biennial CMATH Champions Trip to Germany and ...
(Date:4/24/2017)... ... , ... Today, Bright Pink , a national non-profit organization focusing on the prevention and ... , Bright Pink is proud to announce Katie Thiede as their new Chief Executive Officer. ... as Chairman of the Board and launched a national search to find a visionary ...
(Date:4/24/2017)... ... April 24, 2017 , ... Veteran Theresa James awoke to the ... life forever. , In “Healing Tears,” James depicts every parent’s worst nightmare, when her ... I began journaling conversations and situations throughout my divorce,” James said. “After the death ...
(Date:4/24/2017)... ... 2017 , ... The world-class designers of Happy Gadget Alert ... lifesaving device for the everyday use of parents worldwide. It is a lightweight, ... a child’s vital signs, and detect unusual symptoms or physical patterns. This innovative ...
(Date:4/24/2017)... ... April 24, 2017 , ... symplrTM, a leading provider of ... that Kyle Allain has joined the company as Vice President and General Manager ... provider, payor and managed care solutions. , A seasoned executive with more ...
Breaking Medicine News(10 mins):